anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This invention relates an  alpha -glucosidase inhibitor mildly inhibiting  alpha -glucosidase locally present in the micro-villus of small intestine, a composition principally comprising sugar and containing the inhibitor, a food, a sweetener and a feed. The inhibitor delays the digestion of starch, starch-derived oligosaccharides and sucrose, so that the inhibitor has an action of suppressing rapid increase in blood glucose level and an action of suppressing insulin secretion at a lower level. Thus, the inhibitor is useful for the prophylaxis of obesity and diabetes mellitus. The  alpha -glucosidase inhibitor of the present invention is composed of nucleotide, nucleoside, or base as the structural component of nucleic acid and one or two or more digestible sugars selected from sucrose, starch and starch-derived oligosaccharide. The  alpha -glucosidase inhibitor mildly inhibits the action of  alpha -glucosidase as a digestive enzyme in small intestine, and has effects of suppressing rapid increase in blood glucose level and suppressing insulin secretion at a lower level. In combination with digestible sugars, the  alpha -glucosidase inhibitor is applicable as foods, sweeteners and feeds.
The efficacy of ZERVIATE was established in three randomized, double-masked, placebo-controlled, conjunctival allergen challenge (CAC) clinical trials in patients with a history of allergic conjunctivitis.

Onset and duration of action were evaluated in two of these trials in which patients were randomized to receive ZERVIATE or vehicle ophthalmic solutions. Patients were evaluated with an ocular itching severity score ranging from 0 (no itching) to 4 (incapacitating itch) at several time points after CAC administration. Table 1 displays data from the mean ocular itching severity scores after ocular administration of an antigen using the CAC model. A one unit difference compared to vehicle is considered a clinically meaningful change in the ocular itching severity score. 

Patients treated with ZERVIATE demonstrated statistically and clinically significantly less ocular itching compared to vehicle at 15 minutes and 8 hours after treatment.
The invention provides for an  in vitro  method for producing capsular polysaccharides of  Neisseria meningitidis . The invention also provides capsular polysaccharides obtainable by the methods described herein. The capsular polysaccharides comprise capsular polysaccharide specific for Neisseria meningitidis serogroups W-135, Y, X and A. Also encompassed are chimeric capsular polysaccharides comprising or composed of CPS of Neisseria meningitidis serogroups Y/W-135, W-135/Y, B/Y, C/Y, B/W-135, C/W-135, B/Y/W-135, C/Y/W-135, B/W-135/Y, C/W-135/Y. X/A or A/X. The invention also provides for the use of these capsular polysaccharides foi as pharmaceuticals, particularly as vaccines and/or diagnostics.
The following adverse reactions have been identified during post-approval use of hyaluronidase products. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The most frequently reported adverse reactions have been local injection site reactions.

Hyaluronidase has been reported to enhance the adverse reactions associated with co-administered drug products. Edema has been reported most frequently in association with hypodermoclysis.

Allergic reactions (urticaria, angioedema) have been reported in less than 0.1% of patients receiving hyaluronidase. Anaphylactic-like reactions following retrobulbar block or intravenous injections have occurred, rarely.
All patients who are referred for coronary angiography and require physiological assessment of intermediate lesions will have both RFR and iFR measured during their standard of care procedure. Both the RFR wire (St. Jude Medical (SJM) Aeris Pressure Wire System) and iFR (Volcano Verrata Pressure Wire) wire will be advanced across the lesion with the sensor located at least 3 cm distal from the lesion.
<P>PROBLEM TO BE SOLVED: To provide a method for assaying the primary cause of diabetes, with which a marker gene useful for assaying the primary cause of diabetes is identified and the identified gene is used, a method for screening a compound having effect on prevention or treatment of diabetes, with which expression of the gene is used as an index and to obtain a medicine for preventing or treating diabetes.  <P>SOLUTION: A marker gene useful for judging diabetes is newly identified in order to develop a method for accurately and simply detecting crisis of diabetes in early stages. The method for assaying the primary cause of diabetes is developed by using the expression level of the marker gene as an index. In particular, amounts of gene transcription expressed in bloods of normal rat and GK (Goto-Kakizaki) rat of type II diabetes are compared and a great number of genes recognized to have expression variation specifically to diabetes are selected. These genes are useful as marker genes for assaying the primary cause of diabetes.  <P>COPYRIGHT: (C)2007,JPO&INPIT
An analysis and display system generates and displays a score indicative of whether cancer will recur in a patient. In a learning phase, a phenomic feature of tumor tissue is measured. A corresponding phenomic feature is defined. The phenomic feature may be measured through image analysis of digital images taken of tissue slices stained with IHC-based stains. A genomic feature of the tissue is also measured. This may entail obtaining a probe count indicative of a degree of expression of a particular gene. A bivariate feature is calculated using both the phenomic and genomic information. A network including the bivariate feature is displayed. In a diagnostic phase, raw phenomic and genomic data is obtained from a tissue sample taken from the patient. From the data, a score for the bivariate feature, and scores for the other features, are calculated. The score is a function of the underlying feature scores.
Parent-Youth dyads assigned to the control condition will be asked to download the free Life360 app to their phone during the baseline assessment process and will also be given access to an online suicide resources brochure. Participants will be asked to use the control-condition app and associated materials as often as they would like throughout the duration of the 16 week trial.
The present invention relates to from xylocarpus granatum (Xylocarpus? granatum? does Koenig) separation obtain new triterpene compound xylocarpus granatum element in heptan (xylogranatumin in? G), its preparation method and the purposes in the medicine of preparation treatment tumour. Xylocarpus granatum element in the heptan structural formula of the present invention is as follows. Showing through the experiment of repeatedly anti tumor activity in vitro, it is active that this compound has obvious inhibition tumor cell, is expected in the medicine of preparation treatment tumour and is applied.
Failure of eradication treatment against Helicobacter pylori (H. pylori) is mainly caused by antimicrobial resistance. However, there is no relevant studies have been conducted on the prevalence and trend of antimicrobial resistance, which is considered to have a major determinant of eradication failure. In addition, studying the trend of resistance rate is an important basis for establishing an appropriate strategy for eradication treatment in the future.

Patients who had H. pylori colonies isolated from culture were consecutively enrolled from 2003. From each patient, 1 to 10 H. pylori isolates were isolated. Trends in MIC distribution and prevalence of resistance were investigated for each antimicrobial agent according to time period. Antimicrobi resistances suspected to related with failure of empirical PPI triple, quadruple, and rescue fluoroquinolone-containing treatment were also investigated. Multiple resistance, which is simultaneously resistant to various antibiotics, will also be investigated. Risk factors for the antibiotic resistance will be analyzed.
Patients with Severe Chronic Neutropenia

Confirm the diagnosis of SCN before initiating GRANIX therapy.

MDS and AML have been reported to occur in the natural history of congenital neutropenia without cytokine therapy. Cytogenetic abnormalities, transformation to MDS, and AML have also been observed in patients treated with GRANIX for SCN. Based on available data including a postmarketing surveillance study, the risk of developing MDS and AML appears to be confined to the subset of patients with congenital neutropenia. Abnormal cytogenetics and MDS have been associated with the eventual development of myeloid leukemia. The effect of GRANIX on the development of abnormal cytogenetics and the effect of continued GRANIX administration in patients with abnormal cytogenetics or MDS are unknown. Monitor patients for signs and symptoms of MDS/AML in these settings. If a patient with SCN develops abnormal cytogenetics or myelodysplasia‚ the risks and benefits of continuing GRANIX should be carefully considered.

Patients with Breast and Lung Cancer

MDS and AML have been associated with the use of GRANIX in conjunction with chemotherapy and/or radiotherapy in patients with breast and lung cancer. Monitor patients for signs and symptoms of MDS/AML in these settings.
Participants randomized to the iLet with humalog/novolog first started the insulin-only iLet arm using the insulin analog that they use for their usual care (either Humalog or Novolog) for approximately 5 days. All subjects wore a Dexcom G5 CGM. If randomized to the bionic pancreas arm first, subjects crossed over to the usual care arm following a 2-day washout period.
Repetitive TMS (100 Hz triple pulses) of the dmPFC will be applied daily for four weeks (5 sessions per week on working days, 20 sessions in total). Stimulation triggers will be brain oscillation-synchronized based on EEG extracted over left dmPFC, synchronized with the negative peak of endogenous theta oscillations in left dmPFC.
A heater element for formed components is disclosed, along with the final formed component itself. The heater element is produced by photochemically etching a suitable heater track pattern from porous metallized fabric such a nickel coated woven polyester. The heater element is located within a mold. Thermo-formable material is then applied to the mold and the final component is shaped according to the shape of the mold. The final component has a heater element located within it. The component may have microencapsulated agents for initiation by operation of the heater element. Furthermore, the final component may have one or more digital images printed onto the surface for the purposes of decoration or personalization.
This is a single-center, randomized (study medication assigned to participants by chance), open-label (all people know the identity of the intervention), single application and 2-way Crossover (the same medications provided to all participants but in different sequence) pivotal study to determine the bioequivalence of marketed reference formulation DURAGESIC and the test formulation Fentanyl transdermal system (JNJ-35685-AAA-G021). Approximately 56 healthy participants will participate in this study. Participants will be randomly assigned to 1 of 2 treatment sequences. The study will consist of 3 parts: Screening Phase (within 21 days before the first study drug administration of the first period), an open-label treatment Phase consisting of 2 single-application treatment periods (26 days) and End-of-Study (at the end of Period 2). The total study duration for each participant will be from 43 days to a maximum of 59 days. Participants will receive a single application 100 microgram per hour (mcg/h) dose of DURAGESIC fentanyl transdermal system as Treatment A (Reference) and 100 mcg/h Fentanyl transdermal system (JNJ-35685-AAA-G021) as Treatment B (Test). Bioequivalence will be primarily evaluated by pharmacokinetic parameters. Participants' safety will be monitored throughout the study.
Bupropion is used for treating depression, obesity, and seasonal affective disorder, and for smoking cessation. Bupropion is commonly prescribed, but has complex pharmacokinetics and interindividual variability in metabolism and bioactivation may influence therapeutic response, tolerability, and safety. Bupropion is extensively and stereoselectively metabolized, the metabolites are pharmacologically active, and allelic variation in cytochrome P450 (CYP) 2B6 affects clinical hydroxylation of single-dose bupropion. Genetic effects on stereoselective disposition of steady-state bupropion are not known. In this preplanned secondary analysis of a prospective, randomized, double-blinded, crossover study which compared brand and generic bupropion XL 300 mg drug products, we measured steady-state enantiomeric plasma and urine parent bupropion and primary and secondary metabolite concentrations. This investigation evaluated the influence of genetic polymorphisms in CYP2B6, CYP2C19, and P450 oxidoreductase on the disposition of Valeant Pharmaceuticals Wellbutrin brand bupropion in 67 participants with major depressive disorder. We found that hydroxylation of both bupropion enantiomers was lower in carriers of the CYP2B6*6 allele and in carriers of the CYP2B6 516G>T variant, with correspondingly greater bupropion and lesser hydroxybupropion plasma concentrations. Hydroxylation was 25-50% lower in CYP2B6*6 carriers and one-third to one-half less in 516T carriers. Hydroxylation of the bupropion enantiomers was comparably affected by CYP2B6 variants. CYP2C19 polymorphisms did not influence bupropion plasma concentrations or hydroxybupropion formation but did influence the minor pathway of 4'-hydroxylation of bupropion and primary metabolites. P450 oxidoreductase variants did not influence bupropion disposition. Results show that CYP2B6 genetic variants affect steady-state metabolism and bioactivation of Valeant brand bupropion, which may influence therapeutic outcomes. SIGNIFICANCE STATEMENT: Bupropion, used for depression, obesity, and smoking cessation, undergoes metabolic bioactivation, with incompletely elucidated interindividual variability. We evaluated cytochrome P450 (CYP) 2B6, CYP2C19 and P450 oxidoreductase genetic variants and steady-state bupropion and metabolite enantiomers disposition. Both enantiomers hydroxylation was lower in CYP2B6*6 and CYP2B6 516G>T carriers, with greater bupropion and lesser hydroxybupropion plasma concentrations. CYP2C19 polymorphisms did not affect bupropion or hydroxybupropion but did influence minor 4'-hydroxylation of bupropion and primary metabolites. CYP2B6 variants affect steady-state bupropion bioactivation, which may influence therapeutic outcomes.
OBJECTIVE: Both psychosocial stress and gestational weight gain are independently associated with adverse maternal and fetal outcomes. Studies of the association between psychosocial stress and gestational weight gain (GWG) have yielded mixed results. The objective of this study was to evaluate the association between psychosocial stress and GWG in a large population-based cohort.
METHODS: Data from the nationally representative Pregnancy Risk Assessment Monitoring System (PRAMS) Phase 7 questionnaire 2012-2015 was utilized. Maternal psychosocial stress was assessed through response to questions designed to examine four domains of psychosocial stress (i.e., traumatic, financial, emotional, partner-related) three months prior to or during pregnancy. GWG was categorized using pre-pregnancy BMI and total GWG into inadequate, adequate, or excessive according to the Institute of Medicine's GWG guidelines. Multinomial logistic regression was used to evaluate the association between psychosocial stressors and adequacy of GWG. Analyses took into account complex survey design.
RESULTS: All respondents who delivered ≥ 37 weeks gestation with GWG information available were included in the analysis (n = 119,183). After adjusting for confounders, patients who reported financial stress were more likely to experience excessive versus adequate GWG (RRR 1.09 [95%CI: 1.02-1.17]). Exposure to any of the stressor groups did not significantly increase the risk of inadequate GWG.
CONCLUSIONS: This large, population-based study revealed that among pregnant people in the US, exposure to financial stress is associated with higher risk of excessive GWG. Understanding the role stress plays in GWG will help to inform initiatives targeting this important aspect of prenatal care.
PURPOSE: To prevent formation of blood coagulation in an extracorporeal circuit of an extracorporeal dialysis apparatus, by introducing blood to be treated in the extracorporeal circuit and simultaneously by adding an effective amount of defibrotide to dialysis upstream. CONSTITUTION: At least on the beginning of dialysis apparatus operation in an extracorporeal circuit, an effective amount of defibrotide for preventing formation of blood coagulation is introduced at dialysis membrane upstream at the same time as introduction of blood into an extracorporeal circuit, and a further amount of defibrotide is introduced in succession to the first introduction, if necessary. The first introduction of the defibrotide is preferably conducted by only one injection at an extracorporeal circulation pump upstream. The first introduction of the defibrotide is intended to be a dose of about 200mg and the same dose is injected after 1.5-2 hours from the beginning of the dialysis treatment. Or, the introduction of the defibrotide is conducted by a continuous feeding dose of at least 500mg.  The feeding is begun simultaneously with the introduction to the extracorporeal circuit for blood taken from a patient. The preferable dose of the defibrotide is 600-800mg.
The prevalence of chronic non-communicable diseases such as obesity has noticeably increased in the last decade. The study of these diseases in early life is of paramount importance in determining their course in adult life and in supporting clinical interventions. Recently, attention has been drawn to approaches that study the alteration of metabolic pathways in obese children. In this work, we propose a novel joint modeling approach for the analysis of growth biomarkers and metabolite associations, to unveil metabolic pathways related to childhood obesity. Within a Bayesian framework, we flexibly model the temporal evolution of growth trajectories and metabolic associations through the specification of a joint nonparametric random effect distribution, with the main goal of clustering subjects, thus identifying risk sub-groups. Growth profiles as well as patterns of metabolic associations determine the clustering structure. Inclusion of risk factors is straightforward through the specification of a regression term. We demonstrate the proposed approach on data from the Growing Up in Singapore Towards healthy Outcomes cohort study, based in Singapore. Posterior inference is obtained via a tailored MCMC algorithm, involving a nonparametric prior with mixed support. Our analysis has identified potential key pathways in obese children that allow for the exploration of possible molecular mechanisms associated with childhood obesity.
This is a randomized, double-blind, placebo-controlled study to evaluate the pharmacokinetics (PK), safety, and antiviral effects of galidesivir administered via intravenous (IV) infusion vs. placebo in hospitalized adult subjects with either Yellow Fever (Group A) or COVID-19 (Group B). The study will be conducted in two parts, and each Group (A or B) will proceed independently through the study. Part 1 is a dose ranging study with three sequential cohorts of eight patients each that will be randomized 3:1 to receive IV galidesivir or placebo every 12 hours for 7 days. Upon completion of part 1, an optimized dosing regimen of galidesivir will be selected for part 2, based on part 1 results including safety, PK, viral load reduction, and improvement in signs and symptoms and clinical manifestations, and mortality. In part 2, up to 42 patients will be randomized 2:1 to receive IV galidesivir or placebo. After treatment, the patients will remain hospitalized until resolution of symptoms allows release. All patients will be followed for mortality through Day 56.
The present invention relates to Hemorrhagic Disease Sufferers of Crucian Carp biological control method, it is characterized in that: to cultivation crucian immunity inoculation multivalence carrier bacterin; Described multivalence carrier bacterin is the bacillus subtilis recombinant bacterial strain that utilizes gene engineering method to obtain, does is the Classification And Nomenclature of this recombinant bacterial strain bacillus subtilis HT5304(Bacillus? subtilis? HT5304), being preserved in Chinese Typical Representative culture collection center, does is preserving number CCTCC? No:M2013029. Does the present invention also provide bacillus subtilis HT5304(Bacillus? subtilis? HT5304) application in crucian cultivation disease control. Biological control method of the present invention is by cultivation crucian immunity inoculation multivalence carrier bacterin, realizes the multiple-effect valency immune protection to the viral cause of disease of crucian and bacterial pathogen hemorrhage.
Both Interleukin-6 (IL-6) and Tumor necrosis factor-alpha (TNF-alpha) are substances naturally produced by the body's immune system. Evidence suggests that TNF-alpha production may be excessive or inappropriate in HIV-infected patients. Elevated TNF-alpha levels can result in increased IL-6 production and possibly increased HIV replication. TNFR:Fc is a modification of a natural substance that binds to TNF-alpha and neutralizes its activity. It is postulated that TNFR:Fc may result in decreased activity of TNF-alpha and lower IL-6 levels. HIV-infected patients who receive Interleukin-2 (IL-2) have been shown to have higher TNF-alpha and IL-6 levels than those who do not receive IL-2. It is thought that these higher levels of TNF-alpha and IL-6 may contribute to some of the flu-like symptoms experienced by patients receiving IL-2. By decreasing the amount of IL-6 in the body and by decreasing the action of TNF-alpha in the body, TNFR:Fc may have a role in the treatment of HIV disease or in alleviating some of the symptoms related to IL-2 administration.

Six patients from each of the 3 treatment arms of ACTG 328 (HAART alone, HAART plus intravenous (IV) rhIL-2, and HAART plus subcutaneous (SC) rhIL-2) who are about to be randomized to Step II of ACTG 328 may participate in this prospective, nested substudy. Patients randomized to the Interleukin-2 (IL-2) arms of ACTG 328 are pretreated with TNFR:Fc (administered by infusion over 30 minutes) at week 16 of ACTG 928 (Course 3, Week 28 of ACTG 328), just prior to initiation of IL-2. Those randomized to the highly active antiretroviral therapy (HAART) only arm of ACTG 328 receive treatment with TNFR:Fc at Week 16 of ACTG 928 (Week 28 of ACTG 328).
Breakdown of neuromuscular junctions (NMJs) is an early pathological hallmark of amyotrophic lateral sclerosis (ALS) that blocks neuromuscular transmission, leading to muscle weakness, paralysis and, ultimately, premature death. Currently, no therapies exist that can prevent progressive motor neuron degeneration, muscle denervation, or paralysis in ALS. Here, we report important advances in the development of an optogenetic, neural replacement strategy that can effectively restore innervation of severely affected skeletal muscles in the aggressive SOD1G93A mouse model of ALS, thus providing an interface to selectively control the function of targeted muscles using optical stimulation. We also identify a specific approach to confer complete survival of allogeneic replacement motor neurons. Furthermore, we demonstrate that an optical stimulation training paradigm can prevent atrophy of reinnervated muscle fibers and results in a tenfold increase in optically evoked contractile force. Together, these advances pave the way for an assistive therapy that could benefit all ALS patients.